Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ygyno.2013.07.102
Title: Outcome of 6 fractions of 5.3 Gray HDR brachytherapy in combination with external beam radiotherapy for treatment of cervical cancer
Authors: Koh, W.Y. 
Lim, K. 
Tey, J. 
Lee, K.M.
Lim, G.H.
Choo, B.A. 
Keywords: Brachytherapy
Cervical cancer
Long fractionation
Issue Date: Oct-2013
Citation: Koh, W.Y., Lim, K., Tey, J., Lee, K.M., Lim, G.H., Choo, B.A. (2013-10). Outcome of 6 fractions of 5.3 Gray HDR brachytherapy in combination with external beam radiotherapy for treatment of cervical cancer. Gynecologic Oncology 131 (1) : 93-98. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ygyno.2013.07.102
Abstract: Objective. To review the characteristics, outcomes and toxicities of cervical cancer patients treated with 6 fractions of brachytherapy after external beam radiotherapy (EBRT). Methods. All patients diagnosed with cervical cancer from 2000 to 2009 who were referred for radical treatment and who received 6 fractions of brachytherapy were retrospectively reviewed. Overall survival (OS), disease free survival (DFS), local control (LC), distant control (DC) rate, acute and late toxicitieswere the primary endpoints. Results. Thirty-two patients with mainly advanced stage squamous cell carcinoma were identified and reviewed. Patients received EBRT of 45 to 50.4 Gy in 1.8 Gy daily fractions followed by 6 sessions of 3 channel brachytherapy of 5.3 Gy prescribed to point H. Response rates to treatment were good, with no residual disease in 84% six weeks after the completion of treatment.With a median follow up time of 8.1 years, the five-year OS, DFS, LC and distant control rates were 75%, 68.5%, 92.8% and 76.9% respectively. None of the patients developed any G3-4 acute toxicity but one patient who had advanced disease developed G3-4 proctitis with a fistula formation. Conclusions. HDR brachytherapy utilizing 6 fractions of 5.3 Gy prescribed to point H with concurrent chemoradiation is superior in terms of OS and LC to regimens that deliver a lower EQD2 dose to point A/H and is associated with very low rates of toxicities. © 2013 Elsevier Inc. All rights reserved.
Source Title: Gynecologic Oncology
URI: http://scholarbank.nus.edu.sg/handle/10635/125426
ISSN: 00908258
DOI: 10.1016/j.ygyno.2013.07.102
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

2
checked on Dec 14, 2018

WEB OF SCIENCETM
Citations

1
checked on Nov 21, 2018

Page view(s)

16
checked on Dec 14, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.